Overview

A Study of JNJ-55308942 in the Treatment of Bipolar Depression

Status:
Not yet recruiting
Trial end date:
2024-05-22
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of JNJ-55308942 compared to placebo on symptoms of depression in participants with bipolar disorder (BD) in a major depressive episode (MDE) at Week 6.
Phase:
Phase 2
Details
Lead Sponsor:
Janssen Pharmaceutica N.V., Belgium
Treatments:
JNJ-55308942